| Entry |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Gefitinib (JP18/USAN/INN); Iressa (TN) | ||||||||||||
| Product | IRESSA (AstraZeneca Pharmaceuticals LP) | ||||||||||||
| Formula | C22H24ClFN4O3 | ||||||||||||
| Exact mass | 446.1521 | ||||||||||||
| Mol weight | 446.9024 | ||||||||||||
| Structure |  | ||||||||||||
| Class | Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG03162 EGFR inhibitor | ||||||||||||
| Remark |
| ||||||||||||
| Efficacy | Antineoplastic, Receptor tyrosine kinase inhibitor | ||||||||||||
| Disease | Non-small cell lung cancer (EGFR mutation positive) [DS:H00014] | ||||||||||||
| Target | EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361] | ||||||||||||
| Network |
| ||||||||||||
| Pathway |
| ||||||||||||
| Interaction | |||||||||||||
| Structure map |
| ||||||||||||
| Other map |
| ||||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors L01EB01 Gefitinib D01977 Gefitinib (JP18/USAN/INN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Gefitinib D01977 Gefitinib (JP18/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D01977 Gefitinib (JP18/USAN/INN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG03162 EGFR inhibitor D01977 Gefitinib Drug classes [BR:br08332] Antineoplastic DG03162 EGFR inhibitor D01977 Gefitinib Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) EGFR family EGFR* [HSA_VAR:1956v2] D01977 Gefitinib (JP18/USAN/INN) <JP/US> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D01977 Gefitinib New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D01977 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D01977 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D01977 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01977 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D01977 | ||||||||||||
| Other DBs |
| ||||||||||||
| KCF data | ATOM 31 1 C8x C 14.9262 -11.3780 2 N5x N 14.9262 -12.7769 3 C8y C 16.1377 -13.4764 4 C8y C 17.3492 -12.7769 5 C8y C 17.3492 -11.3780 6 N5x N 16.1377 -10.6786 7 C8x C 18.5607 -13.4764 8 C8y C 19.7722 -12.7769 9 C8y C 19.7722 -11.3780 10 C8x C 18.5607 -10.6786 11 N1b N 16.1377 -14.8754 12 O2a O 20.9864 -10.6770 13 C1a C 22.1998 -11.3776 14 O2a O 20.9864 -13.4779 15 C1b C 22.1998 -12.7773 16 C1b C 23.4120 -13.4764 17 C1b C 24.6236 -12.7769 18 N1y N 25.8350 -13.4764 19 C8y C 17.3499 -15.5752 20 C8x C 17.3499 -16.9737 21 C8y C 18.5614 -17.6732 22 C8y C 19.7728 -16.9737 23 C8x C 19.7728 -15.5752 24 C8x C 18.5614 -14.8758 25 X F 20.9866 -17.6744 26 X Cl 18.5614 -19.0779 27 C1x C 25.8349 -14.8826 28 C1x C 27.0470 -15.5825 29 O2x O 28.2592 -14.8827 30 C1x C 28.2593 -13.4765 31 C1x C 27.0472 -12.7766 BOND 34 1 1 2 1 2 2 3 2 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 2 7 4 7 2 8 7 8 1 9 8 9 2 10 9 10 1 11 5 10 2 12 3 11 1 13 9 12 1 14 12 13 1 15 8 14 1 16 14 15 1 17 15 16 1 18 16 17 1 19 17 18 1 20 11 19 1 21 19 20 2 22 20 21 1 23 21 22 2 24 22 23 1 25 23 24 2 26 19 24 1 27 22 25 1 28 21 26 1 29 18 27 1 30 27 28 1 31 28 29 1 32 29 30 1 33 30 31 1 34 18 31 1 |